Version history

{
  "description": "TDP-43 undergoes phase separation into stress granules, and aberrant transitions to solid aggregates drive ALS-FTD pathology. Small molecules (including GRP75 modulators, nuclear export inhibitors, and RNA chaperones) have shown preclinical promise, but selectivity for pathological vs functional phase separation is unresolved.",
  "gap_id": "gap-006",
  "challenge_type": "open",
  "scope": "gap",
  "initial_bounty_usd": 4000000,
  "current_bounty_usd": 4005598.5,
  "bounty_confidence": 0.72,
  "landscape_score": 0.65,
  "gap_importance_score": 0.92,
  "therapeutic_potential_score": 0.89,
  "urgency_score": 0.88,
  "market_price": 0.5,
  "composite_score": 0.84,
  "debate_count": 0,
  "status": "open",
  "question": "Can small molecules modulating TDP-43 liquid-liquid phase separation dynamics prevent pathological inclusion formation without disrupting normal nuclear TDP-43 RNA splicing function?",
  "domain": "neurodegeneration"
}